Department of Neurology, Sørlandet Hospital, Arendal, Norway.
Acta Neurol Scand. 2013 Mar;127(3):154-60. doi: 10.1111/j.1600-0404.2012.01690.x. Epub 2012 Jun 12.
To identify possible risk factors for reduced health-related quality of life (HRQoL) and fatigue after treated Lyme neuroborreliosis (LNB).
We included 50 patients with LNB and analyzed associations between their demographic, clinical, and laboratory characteristics at baseline and outcome at 30 months assessed by the self-report questionnaires Short Form-36 (SF-36) and Fatigue Severity Scale (FSS).
Lower scores in the SF-36 domain Physical Component Summary were associated with pretreatment symptom duration >6 weeks (B = -11.0, P = 0.001) and non-complete recovery at 4 months (B = -5.5, P = 0.037) (R(2) = 0.35). Lower scores in the SF-36 domain Mental Component Summary were associated with non-complete recovery at 4 months (B = -8.9, P = 0.01 (R(2) = 0.14). Higher FSS scores were associated with pretreatment symptom duration >6 weeks (B = 1.4, P = 0.006), high scores on the composite clinical score pretreatment (B = 0.1, P = 0.003), and non-complete recovery at 4 months (B = 1.6, P = 0.005) (R(2) = 0.46). No laboratory test results were associated with these predefined outcomes.
Delayed treatment start, more symptoms and findings before treatment, and non-complete recovery at 4 months after treatment are possible predictors of a poorer HRQoL and more fatigue 30 months after treated LNB. We did not find age, gender, educational level, involvement of the central nervous system, coexisting diseases, or cerebrospinal fluid findings to be associated with reduced HRQoL or fatigue. Our findings should be replicated in future studies before any conclusions can be drawn.
确定治疗莱姆神经Borreliosis(LNB)后健康相关生活质量(HRQoL)和疲劳降低的可能危险因素。
我们纳入了 50 例 LNB 患者,并分析了基线时的人口统计学、临床和实验室特征与 30 个月时的自我报告问卷短格式 36 项(SF-36)和疲劳严重程度量表(FSS)评估结果之间的关联。
SF-36 生理成分综合评分较低与治疗前症状持续时间>6 周(B=-11.0,P=0.001)和 4 个月时未完全恢复(B=-5.5,P=0.037)有关(R²=0.35)。SF-36 心理成分综合评分较低与 4 个月时未完全恢复有关(B=-8.9,P=0.01[R²=0.14])。FSS 评分较高与治疗前症状持续时间>6 周(B=1.4,P=0.006)、治疗前综合临床评分高(B=0.1,P=0.003)和 4 个月时未完全恢复有关(B=1.6,P=0.005)(R²=0.46)。未发现任何实验室检测结果与这些预定结果相关。
治疗开始延迟、治疗前更多的症状和发现以及 4 个月后治疗未完全恢复可能是治疗后 30 个月 HRQoL 较差和疲劳增加的预测因素。我们未发现年龄、性别、教育程度、中枢神经系统受累、并存疾病或脑脊液发现与 HRQoL 或疲劳降低有关。在得出任何结论之前,这些发现应在未来的研究中得到复制。